Drug Type Small molecule drug |
Synonyms YC-6 |
Target |
Action blockers, antagonists |
Mechanism VDCCs blockers(Voltage-gated calcium channel blockers), mGluRs antagonists(Metabotropic glutamate receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationSpecial Review Project (China) |
Molecular FormulaC19H32O3 |
InChIKeyIFRIPYPBJCUNAG-OTMXHXQLSA-N |
CAS Registry4725-51-3 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Cerebral Small Vessel Diseases | Phase 2 | China | 01 Mar 2022 | |
| Acute Ischemic Stroke | Phase 2 | China | 14 Oct 2020 | |
| Glioma | Phase 2 | China | 14 Oct 2020 | |
| Brain Edema | Phase 2 | China | - | |
| Brain Infarction | Phase 2 | China | - | |
| Brain Injuries | Phase 2 | China | - | |
| Pneumonia | Phase 2 | China | - | |
| Cerebral Hemorrhage | Phase 1 | China | - |
Phase 2 | - | - | sgtvxshvla(achqfhcvho) = 与安慰剂对比,使更多患者免于长期严重残疾 lnklitzrnw (vmdnhzgfff ) View more | Positive | 08 Jan 2024 | ||
安慰剂+取栓治疗 |





